Effect of Switching the Histamine-1 Receptor Antagonist Clemastine to Cetirizine in Paclitaxel Premedication Regimens: The H1-Switch Study
JCO Oncology Practice · 2024
DOI: 10.1200/op.24.00110 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Oncology Practice, 2024. Verfasst von Ruben Malmberg und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Cetirizine, Paclitaxel, Histamine H1 Antagonists, Premedication. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Premedication, including a histamine-1 receptor (H 1 ) antagonist, is recommended to all patients treated with paclitaxel chemotherapy to reduce the incidence of hypersensitivity reactions (HSRs). However, the scientific basis for this premedication is not robust, which provides opportunities for optimization. Substitution of intravenously administered first-generation H 1 antagonist for orally administered second-generation H 1 antagonist could reduce side effects, and improve efficiency and sustainability. This study investigates the efficacy and safety of substituting intravenous clemastine for oral cetirizine as prophylaxis for paclitaxel-induced HSRs. METHODS This single-center, prospective, noninferiority study compares a historic cohort receiving a premedication regimen with intravenous clemastine to a prospective cohort receiving oral cetirizine. Primary end point of the study is HSR grade ≥3. The difference in incidence was calculated together with the 90% CI. We determined that the two-sided 90% CI of HSR grade ≥3 incidence in the oral cetirizine cohort should not be more than 4% higher (ie, the noninferiority margin) compared with the intravenous clemastine cohort. RESULTS Two hundred and twelve patients were included in the oral cetirizine cohort (June 2022 and May 2023) and 183 in the intravenous clemastine cohort. HSR grade ≥3 incidence was 1.6% (n = 3) in the intravenous clemastine cohort and 0.5% (n = 1) in the oral cetirizine cohort, resulting in a difference of –1.2% (90% CI, –3.4 to 1.1). CONCLUSION Premedication containing oral cetirizine is as safe as premedication containing intravenous clemastine in preventing paclitaxel-induced HSR grade ≥3. These findings could contribute to optimization of care for patients and improve efficiency and sustainability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, the Netherlands.
- Department of Medical Oncology, Erasmus University Medical Center Cancer Institute, Rotterdam, the Netherlands.
- Department of Clinical Pharmacy and Maasstad Lab, Maasstad Hospital, Rotterdam, the Netherlands.
ORCID-Profile: Ruben Malmberg, Leni van Doorn, Juul M Cox, Esther Oomen-de Hoop
Zitieren
APA
Malmberg, R., van Doorn, L., Cox, J. M., Daloul, A., Ettafahi, H., Oomen-de Hoop, E., Zietse, M., Bos, M. E. M. M., Koch, B. C. P., & van Leeuwen, R. W. F. (2024). Effect of Switching the Histamine-1 Receptor Antagonist Clemastine to Cetirizine in Paclitaxel Premedication Regimens: The H1-Switch Study. JCO Oncology Practice. https://doi.org/10.1200/op.24.00110
Vancouver
Malmberg R, van Doorn L, Cox JM, Daloul A, Ettafahi H, Oomen-de Hoop E, et al. Effect of Switching the Histamine-1 Receptor Antagonist Clemastine to Cetirizine in Paclitaxel Premedication Regimens: The H1-Switch Study. JCO Oncology Practice. 2024. doi:10.1200/op.24.00110
BibTeX
@article{Malmberg2024,
author = {Malmberg, Ruben and van Doorn, Leni and Cox, Juul M and Daloul, Alaa and Ettafahi, Halima and Oomen-de Hoop, Esther and Zietse, Michiel and Bos, Monique E M M and Koch, Birgit C P and van Leeuwen, Roelof W F},
title = {Effect of Switching the Histamine-1 Receptor Antagonist Clemastine to Cetirizine in Paclitaxel Premedication Regimens: The H1-Switch Study},
journal = {JCO Oncology Practice},
year = {2024},
doi = {10.1200/op.24.00110}
}
EUVIMED